Construction of 124I-trastuzumab for noninvasive PET imaging of HER2 expression: from patient-derived xenograft models to gastric cancer patients

Xiaoyi Guo,Nina Zhou,Zuhua Chen,Teli Liu,Xiaoxia Xu,Xia Lei,Lin Shen,Jing Gao,Zhi Yang,Hua Zhu
DOI: https://doi.org/10.1007/s10120-019-01035-6
2020-01-09
Gastric Cancer
Abstract:Here, we sought to develop a PET radioligand based on trastuzumab labeled with 124I, 124I-trastuzumab, to evaluate its distribution, internal dosimetry, and initial PET images of HER2-positive lesions in gastric cancer (GC) patients.
oncology,gastroenterology & hepatology
What problem does this paper attempt to address?